rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Tirzepatide Cardiovascular Outcomes: Summary of Key Trial Results

RPEP-153392026Huston, Jessica; Orey, Dontia; Ashchi, Andrew; Lachapelle, Andrea Ashchi; Genovese, Ariana; Jackson, Jenna; Ashchi, Ramsey; Ashchi, Towfeeq; Ashchi, Majdi; Sutton, David; Deeb, Wasim; Goldfaden, Rebecca F
evidence
The takeaway

Tirzepatide demonstrated cardiovascular safety in patients with T2D and obesity, with ongoing trials assessing whether it provides active cardioprotection beyond metabolic improvements.

Safe, protection pending

Tirzepatide is cardiovascularly safe, but whether it actively prevents heart attacks and strokes (like semaglutide does) awaits ongoing trial results

What the researchers found

Tirzepatide has demonstrated cardiovascular safety in T2D and obesity. Active cardioprotection (MACE reduction) is being assessed in ongoing dedicated cardiovascular outcome trials.

Why it matters

Millions take tirzepatide. Confirming not just safety but active cardioprotection would solidify its role as a comprehensive cardiometabolic therapy.

How the study worked

Summary of tirzepatide cardiovascular outcome data from clinical trials.

What this study cannot tell us

Short abstract (662 chars). Cardiovascular outcome data still accumulating. Comparative data vs semaglutide limited.

How to read the evidence

Summary of trial data. CV safety established; active cardioprotection not yet proven.

When this study was published

Published in 2025.

The bigger picture

The field awaits tirzepatide's dedicated CV outcome trial results — which could establish it as the first dual agonist with proven cardioprotection.

Questions still open

  • Will tirzepatide show MACE reduction comparable to semaglutide?
  • Does GIP co-agonism add cardiovascular benefit beyond GLP-1?
  • Should tirzepatide be prescribed for CV protection before dedicated trial results?

Common questions

Is tirzepatide safe for the heart?
Yes. Clinical trials have confirmed cardiovascular safety. Whether it actively prevents heart attacks and strokes (beyond its metabolic benefits) is being studied in ongoing trials.
Does tirzepatide protect the heart like semaglutide?
Semaglutide has proven cardiovascular protection. Tirzepatide is cardiovascularly safe, but its dedicated heart outcome trials are still ongoing. The results are expected to be favorable given its metabolic benefits.

Read the original research

Effect of Tirzepatide on Cardiovascular Outcomes.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 26(2), 157-163

View on PubMed ↗Publisher’s paper ↗

Citation

Huston, Jessica; Orey, Dontia; Ashchi, Andrew; Lachapelle, Andrea Ashchi; Genovese, Ariana; Jackson, Jenna; Ashchi, Ramsey; Ashchi, Towfeeq; Ashchi, Majdi; Sutton, David; Deeb, Wasim; Goldfaden, Rebecca F. (2026). Effect of Tirzepatide on Cardiovascular Outcomes.. American journal of cardiovascular drugs : drugs, devices, and other interventions, 26(2), 157-163. https://doi.org/10.1007/s40256-025-00767-4